PHASE III CLINICAL TRIALS IN METASTATIC BREAST CANCER currently open for patient enrollment

Rapid enrollment sought

Budgeted to cover study related costs

PATIENT ELIGIBILITY CRITERIA INCLUDE:

- Measurable stage IV metastatic breast cancer
- Left ventricular ejection fraction ≥50%
- Prior adjuvant doxorubicin allowed (≤300 mg/m²)
- No previous cytotoxic chemotherapy for metastatic breast cancer

Interested investigators please call:

1-888-399-6222

or send E-mail to:

WENG@PFIZER.COM

Sponsored by:

Pfizer

Central Research, Pfizer Inc
Notice to Members of the American Association for Cancer Research
Officers for 1996–1997
President: Louise C. Strong, UT M. D. Anderson Cancer Center, Houston, TX 77030
President-Elect: Donald S. Coffey, Johns Hopkins University School of Medicine, Baltimore, MD 21287-2101
Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 816, Philadelphia, PA 19106-3483

Annual Dues
The annual dues of active members of the American Association for Cancer Research are $160, $40 of which may be applied to a subscription to *Clinical Cancer Research*. Corresponding members of the Association will be charged an appropriate fee to offset second-class postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to Margaret Foti, Executive Director, American Association for Cancer Research, Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483; Telephone: (215) 440-9300; FAX: (215) 440-9313.

Submission of Manuscripts
*Clinical Cancer Research*, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. *Clinical Cancer Research* is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients. All submissions undergo peer review. Papers should be sent to John Mendelsohn, M.D., Editor-in-Chief, *Clinical Cancer Research*, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; Telephone: (212) 639-5878; FAX: (212) 717-3629.

Back Issues and Single Copy Sales of the Journal
Copies of back stock of the journal may be ordered from *Clinical Cancer Research*, P.O. Box 3000, Denville, NJ 07834 [Telephone: (800) 875-2997 or (201) 627-2427; FAX: (201) 627-5872]. As long as supplies permit, single copies will be sold by this company at $12.50/copy. Orders outside the U.S. add $3/copy to offset postage costs.

Advertisements
Advertisement insertion orders and copy must be received one month prior to the date of issue in which the advertisement is to be published. The journal is mailed on approximately the 1st day of the month of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 155 South White Horse Pike, Berlin, NJ 08009 [Telephone: (609) 768-9360; FAX: (609) 753-0064].

Copyright and Permissions
Authors who wish to publish in *Clinical Cancer Research* must formally transfer copyright to the proprietor of the journal, the American Association for Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U.S. Federal Government are not required to transfer copyright to the American Association for Cancer Research, Inc., since these articles are considered to be in the public domain. In the case of articles supported by federal grants or contracts, copyright transfer to the American Association for Cancer Research, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

The Journal will routinely allow authors (or others with the permission of the authors) to include select parts of a copyrighted article in reviews, books, or subsequent papers, upon written request to the AACR Director of Publications. Requests to reproduce an article in its entirety will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate copyright fee. All reproduction requests must include a brief description of intended use and a stamped, self-addressed envelope. Third parties should obtain the approval of the authors before corresponding with the AACR.

Those who wish to photocopy articles should contact the AACR Publications Department [Telephone: (215) 440-9300; FAX: (215) 440-9354].

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

*Clinical Cancer Research* is abstracted and/or indexed in *Cancer Lit*, *Chemical Abstracts*, and *Current Contents (Clinical Medicine).*

*Clinical Cancer Research* (ISSN 1078-0432) is published monthly by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for $40 annually for members and $95 for individual nonmembers. *Clinical Cancer Research* is only available to institutions as a combined subscription with *Cancer Research*. The combined 1996 institutional subscription price of $595 includes $90 for a subscription to *Clinical Cancer Research*. Second-class postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to *Clinical Cancer Research*, P.O. Box 3000, Denville, NJ 07834. Copyright 1996 by the American Association for Cancer Research, Inc. Printed on acid-free paper in the U.S.A.
MAYO CLINIC
DIVISION OF MEDICAL ONCOLOGY
AND MAYO CANCER CENTER
Clinical Research Positions
The Division of Medical Oncology and the NCI-designated Mayo Cancer Center in Rochester, Minnesota, invite applications for two clinical research positions. Clinical investigators with established cancer research programs are encouraged to apply. The Mayo Clinic provides an outstanding environment for investigators interested in conducting translational research with the goal of improving prevention, diagnosis, and treatment of cancer. Interested applicants should submit a statement of research interests, curriculum vitae, bibliography, and list of references to:

James N. Ingle, M.D.
Associate Director for Clinical Research
Mayo Cancer Center
Mayo Clinic
200 First Street, SW
Rochester, MN 55905

Mayo Foundation is an affirmative action and equal opportunity educator and employer.

AMERICAN ASSOCIATION FOR CANCER RESEARCH
The American Association for Cancer Research (AACR) is a professional society of over 11,000 scientists and physicians involved in all aspects of basic, clinical, and translational cancer research. Members of the AACR enjoy:

- subscriptions to Cancer Research, Cell Growth & Differentiation (CG&D), Cancer Epidemiology, Biomarkers & Prevention, and Clinical Cancer Research at reduced member rates
- reduced registration rates at the AACR Annual Meeting, Special Conferences, and International Meetings
- Employment Register, Directory of Members, public education activities, and many other benefits

Special programs to provide enhanced career development opportunities for minority scientists include

- Session on Career Development at Annual Meeting
- Mentorship Program
- Travel Awards to Scientific Meetings

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313 / E-Mail: aacr@aol.com

Proceedings of the
American Association
for Cancer Research
on CD-ROM

- Contains abstracts for more than 4,000 presentations at the 1996 AACR Annual Meeting
- Search by word, phrase, or Boolean expression to pinpoint the abstracts you need
- Operates on Macintosh and Windows platforms

AACR Members - $35
Individual Nonmembers - $45
Institutions - $90
Canada: Add 7% GST; MD residents: Add state sales tax

Order Today!
Telephone: (215) 440-9300; Fax: (215) 440-9313
For more information, e-mail to: aacr@aol.com

This space contributed as a public service.

A CARROT HELPS MORE THAN JUST YOUR EYESIGHT.

A carrot is rich in vitamins A and C, has zero fat, is a good source of fiber, and can help you fight cancer. For more information on fruits and vegetables that can do the same, call 1-800-ACS-2345.
CELL SIGNALING AND CANCER TREATMENT
An American Association for Cancer Research Special Conference in Collaboration with Austrian Cancer Society, British Association for Cancer Research, German Cancer Society and the Austrian Biochemical Society

February 23-28, 1997
Interalpen-Hotel Tyrol
Telts-Buchen, Austria

CONFERENCE CHAIRPERSONS
Hans H. Grunicke / Innsbruck, Austria
Garth Powis / Tucson, AZ
Paul Workman / Macclesfield, England

PROGRAM COMMITTEE
Sara A. Courtneldge / Redwood City, CA
Sylvie Gisselbrecht / Paris, France
Bernd Groner / Freiburg, Germany
Adrian L. Harris / Oxford, England
Peter A. Herrlich / Karlsruhe, Germany
Peter Hilgard / Frankfurt, Germany
Alex Matter / Basel, Switzerland
Frank McCormick / Richmond, CA
Laurent Meijer / Roscoff, France
Michael J. Morin / Groton, CT
Axel Ulrich / Munich, Germany

Keynote Address
Paul Workman / Macclesfield, England

Growth Factor Antagonists and Growth Factor Receptor Blockers
Enrique Rozengurt / London, England
Nancy E. Hynes / Basel, Switzerland
Bernd Groner / Freiburg, Germany
Nicholas Lydon / Basel, Switzerland

Programmed Cell Death: Role in Oncogenesis and Tumor Therapy
Gerard I. Evan / London, England
Caroline Dive / Manchester, England
Douglas R. Green / La Jolla, CA
Donald W. Nicholson / Pointe-Claire-Dorval, Quebec, Canada

Invasion and Metastasis
Max M. Burger / Basel, Switzerland
Louis F. Reichardt / San Francisco, CA
John G. Collard / Amsterdam, The Netherlands
Helmut Ponta / Karlsruhe, Germany

Receptor and Post Receptor Signaling: Mechanisms and Targets in Cancer Chemotherapy
Sara A. Courtneldge / Redwood City, CA
Frank McCormick / Richmond, CA
Nicholas A. Tonks / Cold Spring Harbor, NY
Garth Powis / Tucson, AZ
Ulf R. Rapp / Würzburg, Germany
Alan K. Hall / London, England
Axel Ulrich / Munich, Germany

Angiogenesis
Adrian L. Harris / Oxford, England
Kari K. Alitalo / Helsinki, Finland

Applicants are encouraged to submit abstracts for poster presentation.

Application deadline: November 1, 1996

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300  215-440-9313 (FAX)
E-mail: aacr@aol.com
Programmed Cell Death

October 19-23, 1996
The Sagamore, Bolton Landing (Lake George), New York

CONFERENCE CHAIRPERSONS
Stanley J. Korsmeyer / St. Louis, MO
Shigekazu Nagata / Osaka, Japan
Andrew H. Wyllie / Edinburgh, Scotland

SCIENTIFIC PROGRAM

Keynote Address
Martin C. Raff / London, England

Development
H. Robert Horvitz / Cambridge, MA
Hermann Steller / Cambridge, MA
Stanley J. Korsmeyer / St. Louis, MO

Oncogenesis
Douglas Hanahan / San Francisco, CA
Mina J. Bissell / Berkeley, CA
Eileen P. White / Piscataway, NJ
Gerard I. Evan / London, England

Death Antagonists
Suzanne Cory / Melbourne, Australia
Craig B. Thompson / Chicago, IL
Lois K. Miller / Athens, GA

Death Signals
Shigekazu Nagata / Osaka, Japan
Peter Krammer / Heidelberg, Germany
David V. Goeddel / S. San Francisco, CA
George D. Yancopoulos / Tarrytown, NY

Death Effectors
Junying Yuan / Charlestown, MA
Donald W. Nicholson / Pointe-Claire-Dorval, Quebec, Canada
Vishva Dixit / Ann Arbor, MI
Arnold H. Greenberg / Winnipeg, Manitoba, Canada

Survival Signals
Andrew H. Wyllie / Edinburgh, Scotland
Tadatsugu Taniguchi / Tokyo, Japan
Ken-ichi Arai / Tokyo, Japan

Resistance and Therapeutics
Michael B. Kastan / Baltimore, MD
Richard N. Kolesnick / New York, NY

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for poster presentation.

Application deadline: August 2, 1996

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: aacr@aol.com